Policy | July 26, 2022
Funds for R&D in drug discovery and manufacturing :PIB
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
India imported medical devices worth Rs. 63,200 crore in 2021-22, up 41% from Rs. 44,708 crore in 2020-21
Merck’s first microbiology application and training lab in India
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
Cellutions BioStorage is a comprehensive biomaterial storage and logistics company with a vision to leverage advanced technologies to serve biopharmaceutical companies
Advancing to IND-enabling studies with multiple drug candidates
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Subscribe To Our Newsletter & Stay Updated
